AMETEK Acquires LKC Technologies

Rhea-AI Summary

AMETEK (NYSE: AME) announced on February 3, 2026 the acquisition of LKC Technologies, a provider of portable diagnostic devices for ophthalmic conditions, joining AMETEK's Electronic Instruments Group (EIG).

The deal expands AMETEK's ophthalmic product portfolio, aligns LKC with the Ultra Precision Technologies Reichert business, and supports market expansion in eye‑care diagnostics. AMETEK reported annual sales of approximately $7.5 billion and reaffirmed its growth model emphasizing strategic acquisitions and double‑digit EPS growth over the cycle.

Positive

• Acquisition announced on February 3, 2026, adding LKC Technologies
• Expands ophthalmic portfolio under Ultra Precision Technologies Reichert
• Company scale: AMETEK reported approximately $7.5 billion annual sales

Negative

• None.

Key Figures

Annual sales: approximately $7.5 billion Founded: 1930 NYSE listing tenure: over 95 years

3 metrics

Annual sales approximately $7.5 billion Corporate profile in acquisition release

Founded 1930 Company history in corporate profile

NYSE listing tenure over 95 years AMETEK listing history in corporate profile

Market Reality Check

Price: $228.92 Vol: Volume 2,214,176 vs 20-da...

high vol

$228.92 Last Close

Volume Volume 2,214,176 vs 20-day average 1,324,101 (relative volume 1.67x). high

Technical Price 227.72 is trading above 200-day MA at 188.40 and near 52-week high 229.03.

Peers on Argus

AME gained 1.67% with multiple industrial peers also positive: ROK 2.18%, XYL 1....

AME gained 1.67% with multiple industrial peers also positive: ROK 2.18%, XYL 1.45%, IR 3.31%, OTIS 0.85%, ITW 1.12%, but the momentum scanner did not flag a sector-wide move.

Previous Acquisition Reports

4 past events · Latest: Jul 21 (Positive)

Same Type Pattern 4 events

Date	Event	Sentiment	Move	Catalyst
Jul 21	Acquisition closing	Positive	-0.2%	Completion of FARO Technologies acquisition and integration into Ultra Precision.
May 06	Acquisition agreement	Positive	-1.4%	Definitive agreement to acquire FARO Technologies at a cash premium.
Feb 04	Acquisition announcement	Positive	-2.0%	Acquisition of Kern Microtechnik to add ultra-precision machining solutions.
Oct 31	Acquisition announcement	Positive	+8.5%	Acquisition of Virtek Vision International expanding laser projection offerings.

Pattern Detected

Recent acquisition headlines often showed muted or negative near-term moves, with one notable strong positive reaction.

Recent Company History

Over the past year, AMETEK has consistently used acquisitions to expand capabilities, notably FARO Technologies, Kern Microtechnik, and Virtek Vision, all integrated into the Electronic Instruments Group or Ultra Precision Technologies. These targets added 3D metrology, ultra-precision machining, and laser projection capabilities alongside annual sales ranging from $40 million to $340 million. Today’s LKC Technologies deal continues the strategy of adding specialized instrumentation businesses into EIG, this time focused on ophthalmic diagnostics and eye health monitoring.

Historical Comparison

acquisition

+3.0 %

Average Historical Move

Historical Analysis

In the past year AME had 4 acquisition headlines with an average move of 3.04%. Today’s 1.67% gain is smaller but directionally consistent with that history.

Typical Pattern

Acquisition activity has focused on adding specialized measurement and precision technologies—Virtek’s laser projection, Kern’s ultra-precision machining, and FARO’s 3D metrology—into the Electronic Instruments Group and Ultra Precision divisions, and LKC extends this pattern into ophthalmic diagnostics.

Market Pulse Summary

This announcement highlights AMETEK’s continued use of acquisitions to broaden its portfolio, this t...

Analysis

This announcement highlights AMETEK’s continued use of acquisitions to broaden its portfolio, this time adding LKC’s ophthalmic diagnostic tools into the Electronic Instruments Group. It builds on prior deals like FARO, Kern, and Virtek that extended precision and measurement capabilities. Investors might track how LKC’s technologies integrate alongside AMETEK’s existing Ultra Precision businesses, the contribution toward its $7.5 billion sales base, and any follow-up disclosures in future earnings calls.

Key Terms

ophthalmic, diabetic retinopathy, s&p 500

3 terms

ophthalmic medical

"innovative technologies to enable the effective diagnosis and management of ophthalmic conditions"

Relating to the eye and its care, including medicines, drops, diagnostic tools and surgical devices used to prevent, diagnose or treat eye conditions. Investors care because ophthalmic products form a distinct market with specialized safety approvals, manufacturing needs and payer coverage, so success or failure in this area can drive steady revenue or costly setbacks—think of it as a niche, high‑safety consumer product line for vision health.

diabetic retinopathy medical

"designed to detect early signs of diabetic retinopathy and other serious eye conditions"

Diabetic retinopathy is an eye disease where prolonged high blood sugar damages the tiny blood vessels and nerve tissue at the back of the eye, leading to blurred vision or blindness if untreated. Investors track it because the condition affects a large, growing patient population and drives demand for screening tools, drugs, surgical devices and long-term care—think of it like damaged wiring in a camera that creates a market for repairs and upgrades.

s&p 500 financial

"has been listed on the NYSE for over 95 years and is a component of the S&P 500."

The S&P 500 is a broad stock market index that tracks the performance of 500 large U.S. companies, weighted so bigger firms have a larger impact. Investors use it like a thermometer or benchmark to judge how the overall U.S. stock market or a portfolio is doing; movements in the index influence investor sentiment, fund performance, and many passive investment products that aim to match its returns.

AI-generated analysis. Not financial advice.

BERWYN, Pa., Feb. 3, 2026 /PRNewswire/ -- AMETEK, Inc. (NYSE: AME) today announced the acquisition of LKC Technologies, a leading provider of innovative technologies to enable the effective diagnosis and management of ophthalmic conditions. 

LKC Technologies develops portable devices that help doctors test and monitor eye health. These innovative tools are designed to detect early signs of diabetic retinopathy and other serious eye conditions that can lead to vision loss.

"We are excited to welcome LKC Technologies to AMETEK," said David A. Zapico, AMETEK Chairman and Chief Executive Officer. "LKC Technologies is an excellent strategic fit with our Ultra Precision Technologies Reichert business, providing attractive market expansion opportunities and creating a broader ophthalmic product portfolio.  We look forward to leveraging our respective design and engineering capabilities to further advance patient eye healthcare together."   

LKC Technologies is headquartered in Germantown, MD. They will join AMETEK as part of its Electronic Instruments Group (EIG), a worldwide leader in the design and manufacture of advanced analytical, test and measurement instrumentation for aerospace, medical, power, energy, research and industrial markets.

Corporate Profile
AMETEK (NYSE: AME) is a leading global provider of industrial technology solutions serving a diverse set of attractive niche markets with annual sales of approximately $7.5 billion. The AMETEK Growth Model integrates the Four Growth Strategies - Operational Excellence, Technology Innovation, Global and Market Expansion, and Strategic Acquisitions - with a disciplined focus on cash generation and capital deployment. AMETEK's objective is double-digit percentage growth in earnings per share over the business cycle and a superior return on total capital. Founded in 1930, AMETEK has been listed on the NYSE for over 95 years and is a component of the S&P 500. For more information, visit www.ametek.com.

Contact:
Kevin Coleman
Vice President, Investor Relations and Treasurer
kevin.coleman@ametek.com
Phone: 610-889-5247

View original content:https://www.prnewswire.com/news-releases/ametek-acquires-lkc-technologies-302676826.html

SOURCE AMETEK, Inc.

FAQ

What did AMETEK (AME) announce about LKC Technologies on February 3, 2026?

AMETEK announced it acquired LKC Technologies to expand ophthalmic diagnostics. According to the company, LKC will join AMETEK's Electronic Instruments Group and integrate with the Ultra Precision Technologies Reichert business to broaden the ophthalmic product portfolio.

How does the LKC acquisition affect AMETEK's product lineup and market focus (AME)?

The acquisition broadens AMETEK's ophthalmic diagnostic offerings and market reach. According to the company, LKC's portable devices complement Reichert's precision technologies and create opportunities for expanded eye‑care product solutions and market expansion.

Will the LKC Technologies acquisition materially change AMETEK's size or revenue (AME)?

The announcement does not disclose a purchase price or expected immediate revenue impact. According to the company, AMETEK reported about $7.5 billion in annual sales and views the deal as a strategic expansion of its ophthalmic portfolio.

Which AMETEK division will LKC Technologies join after the acquisition (AME)?

LKC Technologies will join AMETEK's Electronic Instruments Group (EIG) as part of the deal. According to the company, EIG is responsible for analytical, test and measurement instrumentation across medical and industrial markets.

What strategic rationale did AMETEK (AME) provide for acquiring LKC Technologies?

AMETEK said the acquisition is a strategic fit to expand market opportunities in ophthalmics. According to the company, combining LKC with Reichert aims to leverage design and engineering capabilities to advance patient eye healthcare and product offerings.